Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Roivant Sciences (ROIV)
NASDAQ:ROIV
Holding ROIV?
Track your performance easily
ROIV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.56 - $13.06
Previous Close$11.2
Volume8.38M
Average Volume (3M)6.03M
Market Cap
$8.15B
Enterprise Value$3.25B
Total Cash (Recent Filing)$5.39B
Total Debt (Recent Filing)$52.71M
Price to Earnings (P/E)2.0
Beta0.85
Next Earnings
Feb 17, 2025EPS Estimate
-$0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.66
Shares Outstanding727,949,744
10 Day Avg. Volume5,202,379
30 Day Avg. Volume6,034,833
Standard Deviation0.20
R-Squared0.14
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)1.58
Price to Sales (P/S)67.42
Price to Cash Flow (P/CF)-7.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue25.83
Enterprise Value/Gross Profit29.72
Enterprise Value/Ebitda0.72
Forecast
1Y Price Target
$16.17Price Target Upside44.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Roivant Sciences News
PremiumCompany Announcements
Roivant Sciences Reports Q2 2024 Financial Results
PremiumCompany Announcements
Roivant Sciences Acquires Dermavant, Expanding Dermatology Portfolio
Bulls Say, Bears Say
Bulls Say
Financial PositionThe company reported a cash balance of approx. $5.4B.
Research And DevelopmentThe company plans to initiate 4-5 potentially registrational IMVT-1402 programs and studies in a total of 10 indications by Mar. 31, 2026.
Strategic TransactionsThe sale of Dermavant, including VTAMA, to OGN will bring significant upfront and milestone payments, potentially totaling up to $1.2B.
Bears Say
Clinical TrialsPH-ILD in Phase II is a different population than the Phase IB and there's indeed risk.
EarningsThe revenue miss was confounded by the sale of Dermavant which moved Vtama revenues to discontinued ops and contributed to a non-GAAP net loss of ($219M).
Product LaunchVtama's launch in psoriasis has slowed, and analysts are taking a more conservative stance given what has been seen in psoriasis.
---
Ownership Overview
26.17% Insiders
7.73% Mutual Funds
43.94% Other Institutional Investors
9.07% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ROIV FAQ
What was Roivant Sciences’s price range in the past 12 months?
Roivant Sciences lowest stock price was $8.56 and its highest was $13.05 in the past 12 months.
What is Roivant Sciences’s market cap?
Currently, no data Available
When is Roivant Sciences’s upcoming earnings report date?
Roivant Sciences’s upcoming earnings report date is Feb 17, 2025 which is in 92 days.
How were Roivant Sciences’s earnings last quarter?
Roivant Sciences released its earnings results on Nov 12, 2024. The company reported -$0.285 earnings per share for the quarter, missing the consensus estimate of -$0.247 by -$0.038.
Is Roivant Sciences overvalued?
According to Wall Street analysts Roivant Sciences’s price is currently Undervalued.
Does Roivant Sciences pay dividends?
Roivant Sciences does not currently pay dividends.
What is Roivant Sciences’s EPS estimate?
Roivant Sciences’s EPS estimate is -$0.23.
How many shares outstanding does Roivant Sciences have?
Roivant Sciences has 727,949,770 shares outstanding.
What happened to Roivant Sciences’s price movement after its last earnings report?
Roivant Sciences reported an EPS of -$0.285 in its last earnings report, missing expectations of -$0.247. Following the earnings report the stock price went down -1.439%.
Which hedge fund is a major shareholder of Roivant Sciences?
Among the largest hedge funds holding Roivant Sciences’s share is Viking Global Investors LP. It holds Roivant Sciences’s shares valued at 731M.
---
Roivant Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.17 (44.38% Upside)
$16.17 (44.38% Upside)
Blogger Sentiment
Bullish
ROIV Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Decreased
By 8.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $85.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.3%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.48%
12-Months-Change
Fundamentals
Return on Equity
159.08%
Trailing 12-Months
Asset Growth
200.46%
Trailing 12-Months
Company Description
Roivant Sciences
Montes Archimedes Acquisition Corp is a blank check company.
---
ROIV Company Deck
---
ROIV Earnings Call
Q2 2024
0:00 / 0:00
---
ROIV Stock 12 Month Forecast
Average Price Target
$16.17
▲(44.38% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Fate Therapeutics
―
Recursion Pharmaceuticals
―
Denali Therapeutics
―
Best Analysts Covering ROIV
1 Year
1 Year Success Rate
12/12 ratings generated profit
1 Year Average Return
+72.26%
reiterated a buy rating 6 months ago
Copying Louise Chen's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +72.26% per trade.
---